A newly reported wearable device combines ultrasound actuation with microneedle drug delivery to provide both immediate and sustained therapy for gouty arthritis. Published in npj Flexible Electronics, the patch uses ultrasound pulses to trigger on‑demand release and microneedles for sustained local drug depot, offering a potential alternative to systemic dosing. Preclinical testing showed targeted pain relief and reduced inflammatory markers in models of gout, with the device designed for outpatient wearable use. The authors highlight advantages in localized therapy, reduced systemic exposure, and patient‑directed dosing. Medical device developers and pharma companies exploring localized biologic or small‑molecule delivery should track translation steps—manufacturing scale, regulatory device‑drug combination pathway, and human tolerability studies—before clinical adoption.